{{Rsnum
|rsid=1312895
|Chromosome=10
|position=120427312
|Orientation=minus
|GMAF=0.2029
|Assembly=GRCh37
|GenomeBuild=37.1
|dbSNPBuild=131
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
}}
{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 0.9 | 25.7 | 73.5
| HCB | 5.8 | 39.4 | 54.7
| JPT | 8.0 | 34.5 | 57.5
| YRI | 10.9 | 38.1 | 51.0
| ASW | 3.5 | 52.6 | 43.9
| CHB | 5.8 | 39.4 | 54.7
| CHD | 0.9 | 34.9 | 64.2
| GIH | 0.0 | 10.9 | 89.1
| LWK | 8.3 | 38.0 | 53.7
| MEX | 10.5 | 38.6 | 50.9
| MKK | 2.6 | 40.4 | 57.1
| TSI | 2.0 | 20.6 | 77.5
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs1312895
|Name_s=
|Gene_s=-
|Feature=
|Evidence=PubMed ID:19176441
|Annotation=This variant is associated with end-of-induction minimal risidual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) from 2 independent cohorts (GWAS result). Risk Allele: T, MAF= 0.17, combined P value= 1.34E-04.
|Drugs=
|Drug Classes=
|Diseases=Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma
|Curation Level=Curated
|PharmGKB Accession ID=PA162470196
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs1312895
|overall_frequency_n=103
|overall_frequency_d=128
|overall_frequency=0.804688
|n_genomes=51
|n_genomes_annotated=0
|n_haplomes=88
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}